drugset
drugset / Trial / NCT02947152

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

NCT02947152 ↗

Phase 1 Terminated 9 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma

Timeline

Start
2016-12-01
Primary completion
2017-09-14
Completion
2017-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject HKT288 Unknown — Intravenous

Indications

malignant epithelial tumor of ovary renal cell carcinoma